SCHEMBL3105153

SCHEMBL3105153

CCOC(=O)c1cc(-c2ccc(Cl)cc2)oc1C

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.67
RAB9A P51151 2/20 0.67
TARBP2 Q15633 1/20 0.54
HSD17B10 Q99714 1/20 0.52
SMN1; SMN2 Q16637 3/20 0.50
ALDH1A1 P00352 3/20 0.50
KDM4E B2RXH2 1/20 0.50
HPGD P15428 1/20 0.50
MAPK1 P28482 1/20 0.49
GAA P10253 2/20 0.48
ALOX5 P09917 2/20 0.48
S100A4 P26447 1/20 0.48
GCGR P47871 1/20 0.48
ALPL P05186 1/20 0.48
CHRNA7 P36544 2/20 0.46
PKM P14618 1/20 0.46
LMNA P02545 1/20 0.46
ALOX12 P18054 1/20 0.46
HTT P42858 1/20 0.46
KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12348719 0.88 TARBP2 (0.52) NPC1RAB9ATARBP2HSD17B10SMN1; SMN2
SCHEMBL4705049 0.87 ESR1 (0.53) NPC1RAB9AHSD17B10SMN1; SMN2ALDH1A1
SCHEMBL29858707 0.86 TARBP2 (0.54) NPC1RAB9ATARBP2HSD17B10SMN1; SMN2
SCHEMBL29858410 0.86 NPC1 (0.48) NPC1RAB9AHSD17B10SMN1; SMN2ALDH1A1
SCHEMBL4704556 0.86 RAB9A (0.56) NPC1RAB9AHSD17B10SMN1; SMN2ALDH1A1
SCHEMBL3100114 0.85 TSHR (0.54) NPC1RAB9ATARBP2HSD17B10SMN1; SMN2
SCHEMBL3914366 0.85 NPC1 (0.70) NPC1RAB9AHSD17B10SMN1; SMN2ALDH1A1
SCHEMBL29859324 0.84 TARBP2 (0.55) NPC1RAB9ATARBP2HSD17B10SMN1; SMN2
SCHEMBL3075952 0.84 NPC1 (0.50) NPC1RAB9ATARBP2HSD17B10SMN1; SMN2
SCHEMBL27549550 0.83 TNKS (0.48) NPC1RAB9AHSD17B10SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115160270-B Synthesis method of 2,3, 5-trisubstituted furan derivative 浙江大学 2024-01-16 CN disclosed
CN-115160270-A Synthetic method of 2,3,5-trisubstituted furan derivative 浙江大学 2022-10-11 CN disclosed
EP-2210876-B1 HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST TAKEDA PHARMACEUTICAL (JP) 2015-05-20 EP disclosed
US-8309580-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-13 US disclosed
US-20100256156-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-07 US disclosed
EP-2210876-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-07-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256156-A1 HETEROCYCLIC COMPOUND GLP1R, GPR119, GCGR NPC1 3994/4885RAB9A 3790/4885TARBP2 4836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.